Developing a Temporally-Regulated Gene Therapy for Therapeutic Angiogenesis

开发用于治疗性血管生成的时间调控基因疗法

• 批准号: 10832458
• 负责人: Mai Ngo
• 金额: $ 6.95万
• 依托单位: BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-30 至 2024-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10832458
• 关键词: Affect; Alternative Therapies; Angiogenic Factor; Angioplasty; Arteries; Behavior; Biocompatible Materials; Biological; Blood Vessels; Blood flow; Boston; Bypass; Cardiovascular Diseases; Cause of Death; Cell Therapy; Cell secretion; Cells; Cessation of life; Chronic; Clinic; Clinical Trials; Complex; Development; Dose; Endothelial Cells; Engineering; Event; Gene Delivery; Gene Expression; Gene Expression Regulation; Generations; Genes; Genetic; Grant; Growth; Growth Factor; Half-Life; Health; Hindlimb; Hypoxia; Hypoxia Inducible Factor; Immunotherapy; Impairment; In Vitro; Ischemia; Maturation-Promoting Factor; Measures; Mentors; Modeling; Molecular; Operative Surgical Procedures; Oxygen; Patients; Perfusion; Persons; Process; Proliferating; Quality of life; Recombinant Proteins; Recovery; Regenerative Medicine; Response Elements; Role; Signal Transduction; Site; Stroke; Switch Genes; Testing; Tissue Engineering; Tissues; Training; Transcriptional Regulation; Translating; Tube; Universities; Vascular blood supply; Vascularization; Writing; angiogenesis; career; cellular engineering; collaborative environment; comorbidity; cost; design; disability; experience; gene therapy; genetic element; genetically modified cells; improved; in vitro Model; in vivo; in vivo Model; insight; interest; ischemic cardiomyopathy; migration; next generation; novel; overexpression; paracrine; patient subsets; recruit; self organization; sensor; skills; stem cells; success; symposium; synthetic biology; therapeutic angiogenesis; tool

Project Summary/Abstract Cardiovascular diseases affect millions of patients worldwide and account for nearly a third of deaths globally. Ischemia, or a reduced blood supply, occurs in many cardiovascular diseases and is a pressing health challenge. While current treatments primarily focus on re-vascularization of existing blood vessels, a significant sub- population of patients are unable to tolerate the associated surgical procedures due to existing comorbidities. Thus, there is great interest in developing strategies for therapeutic angiogenesis, which seeks to stimulate new vascularization at the ischemic site. While many gene and cell therapies for therapeutic angiogenesis have been tested in clinical trials, a clear benefit for patients remains to be seen. To date, most gene therapies deliver one or two genes to the ischemic site, while cell therapies deliver progenitor or stem cells to produce paracrine factors and self-organize into vasculature. A central limitation of these therapies is the inability to control the temporal presentation of the expressed genes or secreted factors. Angiogenesis is a complex and temporally regulated process, in which angiogenic factors first initiate the formation of a primitive vascular network before maturation factors promote mural cell recruit and vessel stabilization. While studies with growth factors suggest that sequential delivery of angiogenic and maturation factors is beneficial for establishing functional vasculature, how the timing of the angiogenic-to-maturation transition impacts the functionality of the established vasculature is unknown. How tissues naturally sense the correct timing for the angiogenic-to- maturation transition is also unclear, but incorporating a sensor to regulate the expression of angiogenic and maturation genes would be beneficial for creating a gene therapy with controlled dosing and minimal off-target effects. In this proposal, synthetic biology tools will be combined with engineered models of vascularization and an in vivo model of hindlimb ischemia to evaluate how the timing of angiogenic and maturation gene expression impacts functional vascular network formation and recovery from ischemia. In Aim 1, a two-channel genetic switch will be used to establish the relationship between the timing of the angiogenic-to-maturation transition and vascular network functionality. In Aim 2, hypoxia response elements will be used to generate a hypoxia-regulated genetic switch to control the induction of angiogenic and maturation genes. The genetic switch will be evaluated for its ability to rescue perfusion in an in vivo hindlimb ischemia model. The associated training plan will prepare the fellow for an academic career by enabling the fellow to obtain new skillsets in synthetic biology and in vivo models. The fellow will have many opportunities for professional development through mentoring, networking, attending conferences, and experience with grant writing. The fellow will train in the Biological Design Center at Boston University, which holds extensive expertise in molecular, cellular, and tissue engineering and presents an interdisciplinary and collaborative environment for the fellow to develop scientifically and professionally.

项目摘要/摘要 心血管疾病会影响全球数百万患者，占全球死亡的近三分之一。 缺血或血液供应减少，发生在许多心血管疾病中，这是一个紧迫的健康挑战。 尽管目前的治疗主要集中于现有血管的重新血管化，但显着的亚属性 由于现有合并症，患者人群无法忍受相关的手术程序。 因此，人们对制定治疗性血管生成策略有很大的兴趣，该策略试图刺激新的 缺血部位的血管化。虽然许多用于治疗血管生成的基因和细胞疗法已经 在临床试验中测试，对患者的明显好处仍有待观察。迄今为止，大多数基因疗法提供了一个 或两个基因到缺血部位，而细胞疗法则输送祖细胞或干细胞以产生旁分泌因子 并组织成脉管系统。这些疗法的核心局限性是无法控制 表达基因或分泌因素的时间表现。血管生成是一个复杂的 时间调节过程，其中血管生成因子首先启动了原始血管的形成 成熟之前的网络促进壁细胞募集和血管稳定。同时研究成长 因素表明，血管生成和成熟因子的顺序输送对建立有益 功能性脉管系统，血管生成到成熟过渡的时间如何影响 建立的脉管系统尚不清楚。组织如何自然地感觉到血管生成到 - 成熟过渡也不清楚，但结合了一个传感器来调节血管生成和 成熟基因将有益于用受控剂量和最小靶向的基因疗法创建基因疗法 效果。在此建议中，合成生物学工具将与血管化工程模型相结合 后肢缺血的体内模型，用于评估血管生成和成熟基因表达的时间如何 影响功能性血管网络形成和缺血的恢复。在AIM 1中，两通道遗传 开关将用于建立血管生成到成熟过渡的时间与 血管网络功能。在AIM 2中，缺氧反应元素将用于产生低氧调节 遗传转换以控制血管生成和成熟基因的诱导。遗传开关将评估 因为它能够在体内后肢缺血模型中挽救灌注。相关的培训计划将准备 学术生涯的研究员通过使研究员能够获得合成生物学和体内的新技能 型号。该研究员将通过指导，联网，有很多机会进行专业发展的机会 参加会议，并在授予写作方面经验。该研究员将在生物设计中心训练 波士顿大学，在分子，蜂窝和组织工程方面拥有广泛的专业知识，并呈现 该研究员是科学和专业发展的跨学科和协作环境。